Tao Tenghui, Luo Danni, Gao Chenghao, Liu Hui, Lei Zehua, Liu Wenbin, Zhou Chuankun, Qi Dahu, Deng Zhenhan, Sun Xuying, Xiao Jun
Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Sports Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
Front Cell Dev Biol. 2021 Apr 9;9:646386. doi: 10.3389/fcell.2021.646386. eCollection 2021.
Osteoarthritis (OA) is a chronic articular disease characterized by cartilage degradation, subchondral bone remodeling and osteophyte formation. Src homology 2 domain-containing protein tyrosine phosphatase (SHP2) has not been fully investigated in the pathogenesis of OA. In this study, we found that SHP2 expression was significantly increased after interleukin-1β (IL-1β) treatment in primary mouse chondrocytes. Inhibition of SHP2 using siRNA reduced MMP3, MMP13 levels, but increased AGGRECAN, COL2A1, SOX9 expression . On the contrary, overexpression of SHP2 exerted the opposite results and promoted cartilage degradation. Mechanistically, SHP2 activated Wnt/β-catenin signaling possibly through directly binding to β-catenin. SHP2 also induced inflammation through activating Mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB) pathways. Our studies showed that SHP2 knockdown effectively delayed cartilage destruction and reduced osteophyte formation in the mouse model of OA induced by destabilization of the medial meniscus (DMM). Altogether, our study identifies that SHP2 is a novel and potential therapeutic target of OA.
骨关节炎(OA)是一种慢性关节疾病,其特征为软骨降解、软骨下骨重塑和骨赘形成。含Src同源2结构域的蛋白酪氨酸磷酸酶(SHP2)在OA发病机制中的研究尚未充分。在本研究中,我们发现原代小鼠软骨细胞经白细胞介素-1β(IL-1β)处理后SHP2表达显著增加。使用小干扰RNA(siRNA)抑制SHP2可降低基质金属蛋白酶3(MMP3)、基质金属蛋白酶13(MMP13)水平,但增加聚集蛋白聚糖(AGGRECAN)、Ⅱ型胶原(COL2A1)、SRY-盒转录因子9(SOX9)的表达。相反,SHP2过表达则产生相反结果并促进软骨降解。机制上,SHP2可能通过直接结合β-连环蛋白激活Wnt/β-连环蛋白信号通路。SHP2还通过激活丝裂原活化蛋白激酶(MAPK)和核因子κB(NF-κB)通路诱导炎症。我们的研究表明,在半月板内侧失稳(DMM)诱导的OA小鼠模型中,敲低SHP2可有效延缓软骨破坏并减少骨赘形成。总之,我们的研究确定SHP2是OA的一个新的潜在治疗靶点。